Work

Neoadjuvant Gemcitabine, Cisplatin and Durvalumab for Borderline Resectable Cholangiocarcinoma: An Exploratory Analysis of Real-world Outcomes

Year: 2025

Type: article

Source: HPB

DOI: 10.1016/j.hpb.2025.07.763

Authors: Y. Dong, V. Podrascanin, Z. Li, J. Santol, M. Ammann, L. Fonkoua, R. Graham, C. Conboy, N. Tran, S. Warner, R. Smoot, P. Starlinger

Institutions: Sigmund Freud Privatuniversität Wien, Mayo Clinic

Language: Italian

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4414802197

FWCI:

Cites:

Cited by:

Related to: 10